First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Clinical trial NCT05361395 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05361395
- Sponsor
- Amgen
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-24
- Primary completion
- 2028-08-28
- Enrollment
- 184
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.